In addition, a VHL-based proteolysis-targeting chimera (PROTAC) degrader of BRG1, called AU-1533015, was used to treat two non-ccRCC cancer cell lines that express VHL (A375 MA2, HCT116) as well as a normal renal epithelial cell line (HK-2). Here, VHL is linked to nonpapillary renal cell carcinoma.